Associations - EGFR exon 19 deletion

BIOMARKER:

EGFR exon 19 deletion

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval European Pharmaceutical Review - 6 days osimertinib Sensitive : A1 European Pharmaceutical Review - 6d
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials Future Oncol - 3 weeks EGFR inhibitor Sensitive : C3 Future Oncol - 3wk
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: B - Late Trials icotinib Sensitive : B
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1
EGFR exon 19 deletion EGFR exon 19 deletion	Small Cell Lung Cancer Small Cell Lung Cancer	gefitinib Sensitive: C1 - Off-label gefitinib Sensitive : C1
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + osimertinib Sensitive: C2 – Inclusion Criteria gefitinib + osimertinib Sensitive : C2
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	JNJ-61186372 Sensitive: C2 – Inclusion Criteria JNJ-61186372 Sensitive : C2
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	bevacizumab + erlotinib Sensitive: C2 – Inclusion Criteria bevacizumab + erlotinib Sensitive : C2
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + anlotinib Sensitive: C3 – Early Trials erlotinib + anlotinib Sensitive : C3
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	rivoceranib + camrelizumab Resistant: C3 – Early Trials rivoceranib + camrelizumab Resistant : C3
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib + DFP-14323 Sensitive: C3 – Early Trials afatinib + DFP-14323 Sensitive : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES